Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Diclofenac potassium 50mg tablets
1001010AGAAABAB
|
Diclofenac potassium | Diclofenac potassium | Musculoskeletal and Joint Diseases | 2,274 |
|
Voltarol Rapid 50mg tablets
1001010AGBBABAB
|
Voltarol Rapid | Diclofenac potassium | Musculoskeletal and Joint Diseases | 383 |
|
Diclofenac potassium 25mg tablets
1001010AGAAAAAA
|
Diclofenac potassium | Diclofenac potassium | Musculoskeletal and Joint Diseases | 119 |
|
Diclofenac potassium 12.5mg tablets
1001010AGAAACAC
|
Diclofenac potassium | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
First Resort Double Action Pain Relief 12.5mg tablets
1001010AGBEABAC
|
First Resort Double Action Pain Relief | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Joint Pain 12.5mg tablets
1001010AGBDAAAC
|
Voltarol Joint Pain | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Pain-eze 12.5mg tablets
1001010AGBCAAAC
|
Voltarol Pain-eze | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Pain-eze Extra Strength 25mg tablets
1001010AGBCABAA
|
Voltarol Pain-eze | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Rapid 25mg tablets
1001010AGBBAAAA
|
Voltarol Rapid | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.